Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial

Rodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul · 2026

Read Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial by Rodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0360080.txt.

Description

Rodrigo Martinez Alcala and seven colleagues published this research article in PLOS ONE in 2026. It concerns early-stage classic Hodgkin lymphoma, a cancer of the lymph system. The team tested whether staining tumor tissue for three markers, CD68, c-MET, and HLA class II, could help predict how patients would do.

The data come from the H9 trial run jointly by EORTC and GELA, a large randomised treatment study across several countries. As the title states, the marker tests did not show prognostic value in these patients. A clear negative answer like this still helps doctors, because it rules out tests that would add cost and effort without guiding care.

Catalog record

CREATORRodrigo Martinez Alcala, Lydia Visser, Catherine Fortpied, Christophe Fermé, Michel Henry-Amar, Berthe Aleman, Anne Arens, Sidsel Juul
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29539
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0360080

Browse the full library · About the Tower of Babel